Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.67 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.66 |
| ▸ | MMP3 | P08254 | 2/20 | 0.66 |
| ▸ | MMP13 | P45452 | 2/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408613 | 1.00 | MEN1 (0.68) | MEN1KMT2APSMD14PKMPTPN12 | |
| SCHEMBL29408612 | 0.91 | PKM (0.78) | MEN1KMT2APSMD14PKMPTPN12 | |
| SCHEMBL19736229 | 0.91 | PKM (0.78) | MEN1KMT2APSMD14PKMPTPN12 | |
| SCHEMBL29408637 | 0.90 | MEN1 (0.68) | MEN1KMT2APSMD14PKMPTPN12 | |
| SCHEMBL19736167 | 0.90 | MEN1 (0.68) | MEN1KMT2APSMD14PKMPTPN12 | |
| SCHEMBL25992865 | 0.90 | MEN1 (0.68) | MEN1KMT2APSMD14PKMPTPN12 | |
| SCHEMBL10492165 | 0.88 | PTPN12 (0.77) | MEN1KMT2APTPN12PTPN22AKR1B1 | |
| SCHEMBL10492163 | 0.88 | PTPN12 (0.77) | MEN1KMT2APTPN12PTPN22AKR1B1 | |
| SCHEMBL19736165 | 0.86 | PKM (0.69) | MEN1KMT2APSMD14PKMPTPN12 | |
| SCHEMBL29408630 | 0.86 | PKM (0.69) | MEN1KMT2APSMD14PKMPTPN12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307729-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR USE THEREOF | VERSITECH LIMITED (HK) | 2019-10-10 | — | — | US | disclosed |
| WO-2017215552-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307729-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR USE THEREOF | NRDC, NISCH, NEK5 | MEN1 1047/4885KMT2A 4486/4885PSMD14 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.